Innovative Diagnostic Platform Akonni Biosystems has developed a cost-effective and advanced molecular diagnostic platform based on a revolutionary gel-drop microarray technology, enabling the detection of complex infectious diseases such as multi-drug-resistant tuberculosis, which presents significant market demand.

Strong Funding & Recognition The company has successfully attracted multiple grants and investments totaling over $7.3 million, including substantial NIH funding and a Series D investment of $7.5 million from Righton, indicating strong financial backing and validation from reputable industry players.

Award-Winning Innovation Akonni has received prestigious industry awards for product innovation from Frost & Sullivan and recognition for its unique diagnostic platform, enhancing its market credibility and appeal to healthcare providers and government agencies seeking innovative solutions.

Focus on Infectious Diseases With a specific emphasis on testing for multi-drug-resistant infections, especially MDR-TB, Akonni targets a growing global health concern, providing opportunities to collaborate with public health organizations, laboratories, and governments focused on infectious disease control.

Growing Market Position Operating in the molecular diagnostics industry with a current revenue estimate of $1M to $10M and a dedicated team of up to 50 employees, Akonni presents an emerging opportunity for strategic partnerships and sales expansion in the rapidly evolving biotech diagnostics sector.